HESTERBIO

Hester Biosciences Share Price

₹2,437.05 +5.7 (0.23%)

20 Nov, 2024 15:00

SIP TrendupStart SIP in HESTERBIO

Start SIP

Performance

  • Low
  • ₹2,421
  • High
  • ₹2,492
  • 52 Week Low
  • ₹1,293
  • 52 Week High
  • ₹3,379
  • Open Price₹2,452
  • Previous Close₹2,431
  • Volume1,856

Investment Returns

  • Over 1 Month + 1.25%
  • Over 3 Month -1.65%
  • Over 6 Month + 38.37%
  • Over 1 Year + 59.37%
SIP Lightning

Smart Investing Starts Here Start SIP with Hester Biosciences for Steady Growth!

Invest Now

Hester Biosciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 88.3
  • PEG Ratio
  • -10.3
  • Market Cap Cr
  • 2,073
  • P/B Ratio
  • 6.8
  • Average True Range
  • 126.78
  • EPS
  • 27.59
  • Dividend Yield
  • 0.2
  • MACD Signal
  • 29.81
  • RSI
  • 49.93
  • MFI
  • 64.36

Hester Biosciences Financials

Hester Biosciences Technicals

EMA & SMA

Current Price
₹2,437.05
+ 5.7 (0.23%)
pointer
  • stock-down_img
  • Bullish Moving Average 8
  • stock-up_img
  • Bearish Moving Average 8
  • 20 Day
  • ₹2,448.54
  • 50 Day
  • ₹2,428.04
  • 100 Day
  • ₹2,365.71
  • 200 Day
  • ₹2,190.42

Resistance and Support

2449.97 Pivot Speed
  • R3 2,549.78
  • R2 2,520.82
  • R1 2,478.93
  • S1 2,408.08
  • S2 2,379.12
  • S3 2,337.23

What's your outlook on Hester Biosciences?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Hester Biosciences Ltd. is a leading manufacturer of animal healthcare products, specializing in vaccines and veterinary pharmaceuticals. With production facilities in India and Nepal, it serves domestic and international markets, focusing on livestock and poultry healthcare solutions.

Hester Biosciences has an operating revenue of Rs. 312.20 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 9% is okay, ROE of 6% is fair but needs improvement. The company has a debt to equity of 62%, which is bit higher. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 17% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 60 which is a FAIR score but needs to improve its earnings, a RS Rating of 77 which is FAIR indicating the recent price performance, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 29 indicates it belongs to a strong industry group of Medical-Ethical Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock definitely has some strength, you may want to examine it in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Hester Biosciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-28 Quarterly Results
2024-08-02 Quarterly Results
2024-05-10 Audited Results & Dividend
2024-02-02 Quarterly Results
2023-11-07 Quarterly Results

Hester Biosciences F&O

Hester Biosciences Shareholding Pattern

53.73%
0%
0.61%
32.68%
12.98%

About Hester Biosciences

  • NSE Symbol
  • HESTERBIO
  • BSE Symbol
  • 524669
  • Managing Director & CEO
  • Mr. Rajiv Gandhi
  • ISIN
  • INE782E01017

Similar Stocks to Hester Biosciences

Hester Biosciences FAQs

Hester Biosciences share price is ₹2,437 As on 20 November, 2024 | 14:46

The Market Cap of Hester Biosciences is ₹2073.2 Cr As on 20 November, 2024 | 14:46

The P/E ratio of Hester Biosciences is 88.3 As on 20 November, 2024 | 14:46

The PB ratio of Hester Biosciences is 6.8 As on 20 November, 2024 | 14:46

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23